Yıl: 2024 Cilt: 35 Sayı: 2 Sayfa Aralığı: 150 - 157 Metin Dili: İngilizce DOI: 10.5152/tjg.2024.22319 İndeks Tarihi: 10-06-2024

The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib

Öz:
Background/Aims: Pancreatic ductal adenocarcinoma is an extremely deadly type of cancer with a high metastatic potential. Genetic factors in cellular events play an important role in the emergence of this situation. One of these factors is Aurora kinase family members, which play a role in migration, invasion, and cell cycle. In this study, the expression of vascular endothelial growth factor gene, which plays a role in migration, metastasis, and angiogenesis, on cystic fibrosis human pancreatic ductal adenocarcinoma 1 cells of danusertib, a pan-Aurora kinase inhibitor, was examined. Materials and Methods: The half maximal inhibitory concentration (IC 50) value (400 nM) of danusertib in cystic fibrosis human pan- creatic ductal adenocarcinoma 1 cells was determined by the wound-healing test depending on the dose and time and migration with CIM-Plate 16 in the xCELLingence system. In addition, the effect of danusertib on migration was determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) method and vascular endothelial growth factor gene expression. Results: When the dose- and time-dependent danusertib-applied cystic fibrosis human pancreatic ductal adenocarcinoma 1 cells were compared with the control group, it was observed that the wound formed did not close. In the xCELLigence system CIM-Plate 16 migra- tion analysis, it was observed that migration was inhibited in the group administered danusertib in parallel with the wound dehiscence experiment. The gene expressions of vascular endothelial growth factor decreased 0.5-fold at the 24th hour and 0.3-fold at the 48th hour in the Danusertib-administered groups. Conclusion: Danusertib, a pan-Aurora kinase inhibitor, is predicted to be used as a potential agent in pancreatic cancers due to its anti- tumor and anti-metastatic effect.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. Muniraj T, Jamidar PA, Aslanian HR. Pancreatic cancer: a compre- hensive review and update. Disease-A-Month. 2013;59(11):368-402. [CrossRef]
  • 2. Pereira MA, Chio IIC. Metastasis in pancreatic ductal adenocarci- noma: current standing and methodologies. Genes. 2019;11(6):1-22. [CrossRef]
  • 3. Chu LC, Goggins MG, Fishman EK. Diagnosis and detection of pancreatic cancer. Cancer J. 2017;23(6):333-342. [CrossRef]
  • 4. Sánchez-Tilló E, Liu Y, De Barrios O, et al. EMT-activating tran- scription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci. 2012;69(20):3429-3456. [CrossRef]
  • 5. Camargo Barros-Filho M, Guisier F, Rock LD, et al. Tumour sup- pressor genes with oncogenic roles in lung cancer. Genes Cancer. 2019;1-17. [CrossRef]
  • 6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. [CrossRef]
  • 7. Spill F, Reynolds DS, Kamm RD, Zaman MH. Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol. 2016;40:41-48. [CrossRef]
  • 8. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011;147(5):992-1009. [CrossRef]
  • 9. Clark AG, Vignjevic DM. Modes of cancer cell invasion and the role of the microenvironment. Curr Opin Cell Biol. 2015;36:13-22. [CrossRef]
  • 10. von der Mark K, Schöber S, Goodman SL. Integrins in cell migra- tion. Methods Mol Biol. 1999;129:219-230. [CrossRef]
  • 11. Cho SY, Klemke RL. Extracellular-regulated kinase activation and CAS/Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix. J Cell Biol. 2000;149(1):223- 236. [CrossRef]
  • 12. Bozzuto G, Ruggieri P, Molinari A. Molecular aspects of tumor cell migration and invasion. Ann Ist Super Sanita. 2010;46(1):66-80. [CrossRef]
  • 13. Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015;5(5):402-418. [CrossRef]
  • 14. Cavallaro U, Christofori G. Cell adhesion and signalling by cad- herins and Ig-CAMs in cancer. Nat Rev Cancer. 2004;4(2):118-132. [CrossRef]
  • 15. Pedraza-Fariña LG. Mechanisms of oncogenic cooperation in cancer initiation and metastasis. Yale J Biol Med. 2006;79(3-4): 95-103.
  • 16. Hu YY, Zheng MH, Zhang R, Liang YM, Han H. Notch signaling pathway and cancer metastasis. Advances in Experimental Medicine and Biology; 2012:186-198. [CrossRef]
  • 17. Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18(1-2):43-73. [CrossRef]
  • 18. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Trans- duct Target Ther. 2020;5(1):28. [CrossRef]
  • 19. Fallah A, Sadeghinia A, Kahroba H, et al. Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. Biomed Pharmacother. 2019;110:775-785. [CrossRef]
  • 20. Liu CD, Tilch L, Kwan D, McFadden DW. Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer. J Surg Res. 2002;102(1):31-34. [CrossRef]
  • 21. Korc M. Pathways for aberrant angiogenesis in pancreatic can- cer. Mol Cancer. 2003;2:8. [CrossRef]
  • 22. Ai KX, Lu LY, Huang XY, Chen W, Zhang HZ. Prognostic signifi- cance of S100A4 and vascular endothelial growth factor expression in pancreatic cancer. World J Gastroenterol. 2008;14(12):1931-1935. [CrossRef]
  • 23. Pachmayr E, Treese C, Stein U. Underlying mechanisms for dis- tant metastasis - molecular biology. Visc Med. 2017;33(1):11-20. [CrossRef]
  • 24. Zorgetto VA, Silveira GG, Oliveira-Costa JP, Soave DF, Soares FA, Ribeiro-Silva A. The relationship between lymphatic vascular density and vascular endothelial growth factor A (VEGF-A) expression with clinical-pathological features and survival in pancreatic adenocar- cinomas. Diagn Pathol. 2013;8(1):170. [CrossRef]
  • 25. Costache MI, Ioana M, Iordache S, Ene D, Costache CA, Săftoiu A. VEGF expression in pancreatic cancer and other malignancies: a review of the literature. Rom J Intern Med. 2015;53(3):199-208. [CrossRef]
  • 26. Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vas- cular endothelial growth factor in human pancreatic cancer corre- lates with local disease progression. Clin Cancer Res. 1997;3(8):1309-1316.
  • 27. Luo J, Guo P, Matsuda K, et al. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer. 2001;92(3):361-369. [CrossRef]
  • 28. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell. 1998;94(6):715-725. [CrossRef]
  • 29. Cicenas J, Cicenas E. Multi-kinase inhibitors, AURKs and cancer. Med Oncol. 2016;33(5):43. [CrossRef]
  • 30. Baldini E, Tuccilli C, Sorrenti S, et al. Aurora kinases: new molecu- lar targets for the therapy of aggressive thyroid Cancers. Anti-Can- cer Drugs – Nat, Synth Cell. 2016:96-118. [CrossRef]
  • 31. Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibi- tors – Rising stars in cancer therapeutics? Mol Cancer Ther. 2010;9(2):268-278. [CrossRef]
  • 32. Katayama H, Sen S. Aurora kinase inhibitors as anticancer mol- ecules. Biochim Biophys Acta. 2010;1799(10-12):829-839. [CrossRef]
  • 33. Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J. Aurora kinases: novel therapy targets in cancers. Oncotarget. 2017;8(14):23937- 23954. [CrossRef]
  • 34. Bolanos-Garcia VM. Aurora kinases. Int J Biochem Cell Biol. 2005;37(8):1572-1577. [CrossRef]
  • 35. Kirbiyik IA, Ozcimen AA. The effect of danusertib, an aurora kinase inhibitor, onto the cytotoxicity, cell cycle and apoptosis in pancreatic ductal adenocarcinoma cells. J Cancer Res Ther. 2021;17(6):1419-1424. [CrossRef]
  • 36. Yuan CX, Zhou ZW, Yang YX, et al. Danusertib, a potent pan- Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal tran- sition involving the Pi3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells. Drug Des Dev Ther. 2015;9:1293-1318. [CrossRef]
  • 37. Xie L, Meyskens FL. The pan-Aurora kinase inhibitor, PHA- 739358, induces apoptosis and inhibits migration in melanoma cell lines. Melanoma Res. 2013;23(2):102-113. [CrossRef]
  • 38. Carpinelli P, Ceruti R, Giorgini ML, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther. 2007;6(12 Pt 1):3158-3168. [CrossRef]
  • 39. Hata T, Furukawa T, Sunamura M, et al. RNA interference target- ing aurora kinase A suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 2005;65(7):2899-2905. [CrossRef]
  • 40. Schoumacher RA, Ram J, Iannuzzi MC, et al. A cystic fibrosis pan- creatic adenocarcinoma cell line. Proc Natl Acad Sci U S A. 1990;87(10):4012-4016. [CrossRef]
  • 41. Zhao W, Li D, Liu Z, Zheng X, Wang J, Wang E. Spiclomazine induces apoptosis associated with the suppression of cell viability, migration and invasion in pancreatic carcinoma cells. PLoS One. 2013;8(6):e66362. [CrossRef]
  • 42. Cicenas J. The Aurora kinase inhibitors in cancer research and therapy. J Cancer Res Clin Oncol. 2016;142(9):1995-2012. [CrossRef]
  • 43. Gontarewicz A, Balabanov S, Keller G, et al. Simultaneous target- ing of Aurora kinases and bcr-abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR- ABL mutations including T315I. Blood. 2008;111(8):4355-4364. [CrossRef]
  • 44. Li JP, Yang YX, Liu QL, et al. The pan-inhibitor of aurora kinases danusertib induces apoptosis and autophagy and suppresses epith elial-to-mesenchymal transition in human breast cancer cells. Drug Des Devel Ther. 2015;9:1027-1062. [CrossRef]
  • 45. Zhu Q, Yu X, Zhou ZW, et al. A quantitative proteomic response of hepatocellular carcinoma Hep3B cells to danusertib, a pan-Aurora kinase inhibitor. J Cancer. 2018;9(12):2061-2071. [CrossRef]
  • 46. Gontarewicz A, Brümmendorf TH. Danusertib (formerly PHA- 739358) – a novel combined pan-aurora kinases and third genera- tion bcr-abl tyrosine kinase inhibitor. Small Mol Oncol. 2010;184:199-214.
  • 47. Cohen RB, Jones SF, Aggarwal C, et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infu- sion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res. 2009;15(21):6694-6701. [CrossRef]
  • 48. Keleg S, Büchler P, Ludwig R, Büchler MW, Friess H. Invasion and metastasis in pancreatic cancer. Mol Cancer. 2003;2(1):14. [CrossRef]
  • 49. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vas- cular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res. 1994;85(10):1045-1049. [CrossRef]
  • 50. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumori- genesis in a mouse model of experimental liver metastasis. J Clin Invest. 1995;95(4):1789-1797. [CrossRef]
APA Alabaş E, OZÇIMEN A (2024). The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib. , 150 - 157. 10.5152/tjg.2024.22319
Chicago Alabaş Erkan,OZÇIMEN AHMET ATA The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib. (2024): 150 - 157. 10.5152/tjg.2024.22319
MLA Alabaş Erkan,OZÇIMEN AHMET ATA The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib. , 2024, ss.150 - 157. 10.5152/tjg.2024.22319
AMA Alabaş E,OZÇIMEN A The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib. . 2024; 150 - 157. 10.5152/tjg.2024.22319
Vancouver Alabaş E,OZÇIMEN A The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib. . 2024; 150 - 157. 10.5152/tjg.2024.22319
IEEE Alabaş E,OZÇIMEN A "The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib." , ss.150 - 157, 2024. 10.5152/tjg.2024.22319
ISNAD Alabaş, Erkan - OZÇIMEN, AHMET ATA. "The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib". (2024), 150-157. https://doi.org/10.5152/tjg.2024.22319
APA Alabaş E, OZÇIMEN A (2024). The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib. Turkish Journal of Gastroenterology, 35(2), 150 - 157. 10.5152/tjg.2024.22319
Chicago Alabaş Erkan,OZÇIMEN AHMET ATA The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib. Turkish Journal of Gastroenterology 35, no.2 (2024): 150 - 157. 10.5152/tjg.2024.22319
MLA Alabaş Erkan,OZÇIMEN AHMET ATA The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib. Turkish Journal of Gastroenterology, vol.35, no.2, 2024, ss.150 - 157. 10.5152/tjg.2024.22319
AMA Alabaş E,OZÇIMEN A The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib. Turkish Journal of Gastroenterology. 2024; 35(2): 150 - 157. 10.5152/tjg.2024.22319
Vancouver Alabaş E,OZÇIMEN A The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib. Turkish Journal of Gastroenterology. 2024; 35(2): 150 - 157. 10.5152/tjg.2024.22319
IEEE Alabaş E,OZÇIMEN A "The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib." Turkish Journal of Gastroenterology, 35, ss.150 - 157, 2024. 10.5152/tjg.2024.22319
ISNAD Alabaş, Erkan - OZÇIMEN, AHMET ATA. "The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib". Turkish Journal of Gastroenterology 35/2 (2024), 150-157. https://doi.org/10.5152/tjg.2024.22319